Shares of Spark Therapeuticssurged nearly 20 percentWednesday after the Philadelphia gene therapy company revealed promisingresults from a study of its potential one-time therapy for hemophilia A.

Preliminary data from a Phase 1/2 dose-escalation clinical trial of SPK-8011showed human proof-of-concept in three participants, the drug maker said.

The encouraging start for hemophilia A reinforces the strength of our gene-therapy platform and positions us well to potentially transform the current treatment approach for this life-altering disease with a onetime intervention, said Katherine A. High, Sparks president and chief scientific officer.

Hemophilia is a genetic disorder caused by missing or defective factor VIII, a clotting protein. About 20,000 Americans live with hemophilia. The way the medical community has addressed the disorder is to ensure that patients have continuous injections of blood-clotting factors. Patients infuse themselves two to three times a week for the rest of their lives.

In the study, three patientsreceived infusions of vector genomes and no serious adverse events were reported, Spark said. One person has been followed for 23 weeks and another for 12 weeks. The initial dose created stable factor VIII levels with no spontaneous bleeds, the company said.

For a third patient, the genome dose was doubled and that persons factor VIII activity level is tracking proportionally higher, consistent with the dose escalation. So far, the drug has been safe and well tolerated, with no reports of serious adverse events, no thrombotic events, no immune responses, and no elevations of liver enzymes, the company said.

The data must be considered preliminary and one must be careful not to overinterpret them, said Cowen & Co. analyst Phil Nadeau in a client update. That being said, we find the results quite encouraging.

Despite a low starting dose, the gene therapy produced stable and clinically meaningful factor levels sufficient to prevent spontaneous bleeds in patients, Nadeau said. Moreover, the safety profile is clean thus far. The results suggest the company may be able to achieve greater factor levels at higher doses. We find SPK-8011s early data encouraging, and think they suggest that Spark has a viable and competitive hemophilia A program.

Spark will present full data at a medical conference in December.

The hemophilia A results, though early, along with previously reported data for the companys hemophilia B candidate, confirm Sparks thought leadership in hemophilia gene therapy, and the likelihood of achieving a leading position in the overall hemophilia market (currently $7 billion, growing to $14 billion in 2030), Chardan Capital Markets analyst Gbola Amusa said in a client note. Chardan raised its peak earnings forecast for Sparks hemophilia A therapy to $1.3 billion, up from $397 million.

Sparks lead drug, a treatment for rare inherited blindness, is under priority review with the U.S. Food and Drug Administration, with a possible approval date of Jan. 12, 2018. If approved, it would be the first gene therapy for a genetic disease in the United States.

Spark, which was spun out of Childrens Hospital of Philadelphia, reported a second-quarter financial loss of $74.4 million in the quarter ended June 30, or $2.40 per share, on revenue of $1.5 million from itscollaboration with Pfizer Inc. for hemophilia B.

Sparks shares have risen 58 percent since Jan. 1 and 37 percent in the last 12 months. The stock closed up 19.72 percent, or $13.13, to $79.72.

Published: August 2, 2017 1:12 PM EDT

We recently asked you to support our journalism. The response, in a word, is heartening. You have encouraged us in our mission to provide quality news and watchdog journalism. Some of you have even followed through with subscriptions, which is especially gratifying. Our role as an independent, fact-based news organization has never been clearer. And our promise to you is that we will always strive to provide indispensable journalism to our community. Subscriptions are available for home delivery of the print edition and for a digital replica viewable on your mobile device or computer. Subscriptions start as low as 25 per day. We're thankful for your support in every way.

Go here to see the original:

Philly gene therapy company reports early promising hemophilia A results - Philly.com